NASDAQ:CDMO - Avid Bioservices Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.56 -0.01 (-0.28 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$3.57
Today's Range$3.52 - $3.62
52-Week Range$2.24 - $5.78
Volume193,100 shs
Average Volume394,453 shs
Market Capitalization$191.65 million
P/E Ratio-4.05
Dividend YieldN/A
Beta2.2

About Avid Bioservices (NASDAQ:CDMO)

Avid Bioservices logoAvid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support. It also offers various process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. is based in Tustin, California.

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100

Debt

Debt-to-Equity RatioN/A
Current Ratio1.13
Quick Ratio0.74

Price-To-Earnings

Trailing P/E Ratio-4.05
Forward P/E Ratio-5.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$57.63 million
Price / Sales3.43
Cash FlowN/A
Price / CashN/A
Book Value$1.26 per share
Price / Book2.83

Profitability

EPS (Most Recent Fiscal Year)($0.88)
Net Income$-28,150,000.00
Net Margins-46.62%
Return on Equity-57.49%
Return on Assets-28.83%

Miscellaneous

Employees323
Outstanding Shares55,550,000

Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices?

Avid Bioservices announced a dividend on Wednesday, March 7th. Shareholders of record on Monday, March 19th will be given a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date of this dividend is Friday, March 16th. View Avid Bioservices' Dividend History.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices (NASDAQ:CDMO) announced its quarterly earnings data on Monday, March, 12th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.09. The biopharmaceutical company earned $6.82 million during the quarter, compared to analysts' expectations of $8.95 million. Avid Bioservices had a negative net margin of 46.62% and a negative return on equity of 57.49%. View Avid Bioservices' Earnings History.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release their next quarterly earnings announcement on Friday, July, 13th 2018. View Earnings Estimates for Avid Bioservices.

What price target have analysts set for CDMO?

3 brokerages have issued twelve-month price targets for Avid Bioservices' stock. Their predictions range from $4.00 to $10.00. On average, they anticipate Avid Bioservices' share price to reach $7.00 in the next twelve months. View Analyst Ratings for Avid Bioservices.

Who are some of Avid Bioservices' key competitors?

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the folowing people:
  • Mr. Paul J. Lytle, CFO & Principal Accounting Officer (Age 50)
  • Mr. Mark R. Ziebell J.D., VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Dr. Shelley P. M. Fussey Ph.D., VP of Intellectual Property (Age 52)
  • Ms. Tracy L. Kinjerski, VP of Bus. Operations
  • Dr. Steven M. Chamow, Head of Technical Services (Age 64)

Has Avid Bioservices been receiving favorable news coverage?

Media coverage about CDMO stock has been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Avid Bioservices earned a news impact score of 0.22 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.88 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different of institutional and retail investors. Top institutional investors include Bandera Partners LLC (1.84%), BlackRock Inc. (1.37%), CVI Holdings LLC (1.07%), Schwartz Investment Counsel Inc. (0.86%), Wells Fargo & Company MN (0.40%) and Stifel Financial Corp (0.34%). View Institutional Ownership Trends for Avid Bioservices.

Which institutional investors are buying Avid Bioservices stock?

CDMO stock was purchased by a variety of institutional investors in the last quarter, including Bandera Partners LLC, BlackRock Inc., CVI Holdings LLC, Schwartz Investment Counsel Inc., Wells Fargo & Company MN, Stifel Financial Corp, Millennium Management LLC and Northern Trust Corp. View Insider Buying and Selling for Avid Bioservices.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $3.56.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $191.65 million and generates $57.63 million in revenue each year. The biopharmaceutical company earns $-28,150,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Avid Bioservices employs 323 workers across the globe.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]


MarketBeat Community Rating for Avid Bioservices (CDMO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  361
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Avid Bioservices (NASDAQ:CDMO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Avid Bioservices in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 96.63%. The high price target for CDMO is $10.00 and the low price target for CDMO is $4.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$10.00$10.00
Price Target Upside: 96.63% upside196.61% upside136.97% upside221.54% upside

Avid Bioservices (NASDAQ:CDMO) Consensus Price Target History

Price Target History for Avid Bioservices (NASDAQ:CDMO)

Avid Bioservices (NASDAQ:CDMO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018Wells Fargo & CoInitiated CoverageOutperformHighView Rating Details
3/13/2018First AnalysisInitiated CoverageOverweight$4.00MediumView Rating Details
1/5/2018Noble FinancialReiterated RatingBuyLowView Rating Details
9/13/2016Roth CapitalReiterated RatingNeutral$3.50N/AView Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$7.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Avid Bioservices (NASDAQ:CDMO) Earnings History and Estimates Chart

Earnings by Quarter for Avid Bioservices (NASDAQ:CDMO)

Avid Bioservices (NASDAQ:CDMO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20181($0.08)($0.08)($0.08)
Q1 20191($0.06)($0.06)($0.06)
Q2 20191($0.05)($0.05)($0.05)
Q3 20191($0.03)($0.03)($0.03)

Avid Bioservices (NASDAQ CDMO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/13/2018        
3/12/2018Q3 2018($0.14)($0.23)$8.95 million$6.82 millionViewListenView Earnings Details
12/11/2017Q2 2018($0.12)($0.27)$13.54 million$12.78 millionViewN/AView Earnings Details
9/11/2017Q1 2018($0.12)($0.06)$15.22 million$27.08 millionViewN/AView Earnings Details
7/14/2017Q4 2017($0.07)($0.16)$22.57 million$17.90 millionViewN/AView Earnings Details
3/13/2017Q3 2017($0.21)($0.28)$14.02 million$10.75 millionViewN/AView Earnings Details
12/12/2016Q217($0.21)($0.14)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.28)($0.35)$13.08 million$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.21)($0.35)$15.80 million$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.49)($0.56)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.63)($0.49)$7.35 million$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.56)($0.56)$7.96 million$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.56)($0.49)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.56)($0.56)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.49)($0.49)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.42)($0.56)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.49)($0.42)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.42)($0.42)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.35)($0.35)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.35)($0.35)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.42)($0.42)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.49)($0.28)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.63)($0.56)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.77)($0.49)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.91)($0.70)ViewN/AView Earnings Details
3/9/2012($0.91)($0.91)ViewN/AView Earnings Details
12/12/2011($0.91)($1.12)ViewN/AView Earnings Details
9/9/2011($0.98)($0.77)ViewN/AView Earnings Details
7/14/2011Q4 2011($1.12)($1.05)ViewN/AView Earnings Details
3/11/2011Q3 2011($0.91)($0.97)ViewN/AView Earnings Details
12/9/2010Q2 2011($0.84)($0.92)ViewN/AView Earnings Details
9/9/2010Q1 2011($0.70)($0.99)ViewN/AView Earnings Details
7/14/2010Q4 2010($0.70)($1.12)ViewN/AView Earnings Details
3/11/2010Q3 2010($0.22)ViewN/AView Earnings Details
12/10/2009Q2 2010($0.41)ViewN/AView Earnings Details
9/3/2009Q1 2010($0.35)ViewN/AView Earnings Details
7/14/2009Q4 2009($0.70)ViewN/AView Earnings Details
3/11/2009Q3 2009($0.35)($0.52)ViewN/AView Earnings Details
12/10/2008Q2 2009($0.70)($0.70)ViewN/AView Earnings Details
9/9/2008Q1 2009($0.77)ViewN/AView Earnings Details
7/14/2008Q4 2008($0.70)ViewN/AView Earnings Details
3/11/2008Q3 2008($0.94)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Avid Bioservices (NASDAQ:CDMO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/7/2018$0.65633/16/20183/19/20184/2/2018
(Data available from 1/1/2013 forward)

Insider Trades

Avid Bioservices (NASDAQ CDMO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.53%
Institutional Ownership Percentage: 19.00%
Insider Trading History for Avid Bioservices (NASDAQ:CDMO)
Institutional Ownership by Quarter for Avid Bioservices (NASDAQ:CDMO)

Avid Bioservices (NASDAQ CDMO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Mark R BamforthDirectorBuy50,000$2.25$112,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Avid Bioservices (NASDAQ CDMO) News Headlines

Source:
DateHeadline
Avid Bioservices Announces Appointment of Magnus Schroeder, Ph.D., as Vice President of Process SciencesAvid Bioservices Announces Appointment of Magnus Schroeder, Ph.D., as Vice President of Process Sciences
finance.yahoo.com - May 8 at 8:46 AM
Avid Bioservices (CDMO) Receives Average Recommendation of "Buy" from AnalystsAvid Bioservices (CDMO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 4 at 1:34 AM
Avid Bioservices (CDMO) Upgraded by ValuEngine to "Sell"Avid Bioservices (CDMO) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 3 at 10:18 PM
Avid Bioservices Provides Update on Ongoing Expansion of Process Development Capabilities and Laboratory ...Avid Bioservices Provides Update on Ongoing Expansion of Process Development Capabilities and Laboratory ...
globenewswire.com - April 25 at 8:44 AM
Does Avid Bioservices Inc (NASDAQ:CDMO) Fall With The Market?Does Avid Bioservices Inc (NASDAQ:CDMO) Fall With The Market?
finance.yahoo.com - April 19 at 8:44 AM
Avid Bioservices (CDMO) Upgraded at BidaskClubAvid Bioservices (CDMO) Upgraded at BidaskClub
www.americanbankingnews.com - April 17 at 11:58 PM
SA Interview: Identifying Compelling Off-The-Run Opportunities For 2018 With Seneca Park ResearchSA Interview: Identifying Compelling Off-The-Run Opportunities For 2018 With Seneca Park Research
seekingalpha.com - April 15 at 9:45 AM
Avid Bioservices Inc (CDMO) Given Average Rating of "Buy" by AnalystsAvid Bioservices Inc (CDMO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 9 at 1:27 AM
Avid Bioservices (CDMO) Lifted to "Hold" at Zacks Investment ResearchAvid Bioservices (CDMO) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 6:04 PM
Avid Bioservices Inc (CDMO) Expected to Post Quarterly Sales of $7.26 MillionAvid Bioservices Inc (CDMO) Expected to Post Quarterly Sales of $7.26 Million
www.americanbankingnews.com - April 5 at 3:42 AM
Avid Bioservices (CDMO) Stock Rating Lowered by ValuEngineAvid Bioservices (CDMO) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM
-$0.12 EPS Expected for Avid Bioservices Inc (CDMO) This Quarter-$0.12 EPS Expected for Avid Bioservices Inc (CDMO) This Quarter
www.americanbankingnews.com - April 3 at 1:56 PM
Avid Bioservices (CDMO) Now Covered by Analysts at Wells Fargo & CoAvid Bioservices (CDMO) Now Covered by Analysts at Wells Fargo & Co
www.americanbankingnews.com - March 15 at 5:02 PM
Avid Bioservices Inc (CDMO) Receives Consensus Rating of "Buy" from BrokeragesAvid Bioservices Inc (CDMO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 15 at 4:00 PM
Research Analysts Issue Forecasts for Avid Bioservices Incs FY2018 Earnings (CDMO)Research Analysts Issue Forecasts for Avid Bioservices Inc's FY2018 Earnings (CDMO)
www.americanbankingnews.com - March 15 at 9:40 AM
Benzingas Top Upgrades, Downgrades For March 14, 2018 - BenzingaBenzinga's Top Upgrades, Downgrades For March 14, 2018 - Benzinga
www.benzinga.com - March 14 at 6:32 PM
Avid Bioservices Reports Financial Results for Third Quarter of Fiscal Year 2018 and Recent Developments - GlobeNewswire (press release)Avid Bioservices Reports Financial Results for Third Quarter of Fiscal Year 2018 and Recent Developments - GlobeNewswire (press release)
globenewswire.com - March 14 at 6:32 PM
Avid Bioservices (CDMO) Coverage Initiated by Analysts at First AnalysisAvid Bioservices (CDMO) Coverage Initiated by Analysts at First Analysis
www.americanbankingnews.com - March 13 at 9:08 PM
Avid Bioservices to Participate at Upcoming CDMO Industry Conferences - GlobeNewswire (press release)Avid Bioservices to Participate at Upcoming CDMO Industry Conferences - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:57 AM
Avid Bioservices (CDMO) Issues  Earnings ResultsAvid Bioservices (CDMO) Issues Earnings Results
www.americanbankingnews.com - March 12 at 7:36 PM
Avid Bioservices Reports Financial Results for Third Quarter of Fiscal Year 2018 and Recent DevelopmentsAvid Bioservices Reports Financial Results for Third Quarter of Fiscal Year 2018 and Recent Developments
finance.yahoo.com - March 12 at 6:10 PM
Avid Bioservices Inc (CDMO) Declares Dividend of $0.66Avid Bioservices Inc (CDMO) Declares Dividend of $0.66
www.americanbankingnews.com - March 11 at 8:19 AM
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred StockAvid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
finance.yahoo.com - March 7 at 5:58 PM
Avid Bioservices (CDMO) Set to Announce Quarterly Earnings on MondayAvid Bioservices (CDMO) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 6 at 9:19 AM
Avid Bioservices to Present at the 30th Annual ROTH ConferenceAvid Bioservices to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 8:43 AM
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018
finance.yahoo.com - March 5 at 8:46 AM
Head to Head Comparison: Avid Bioservices (CDMO) and Novus Therapeutics (NVUS)Head to Head Comparison: Avid Bioservices (CDMO) and Novus Therapeutics (NVUS)
www.americanbankingnews.com - March 5 at 1:14 AM
Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of ... - GlobeNewswire (press release)Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of ... - GlobeNewswire (press release)
globenewswire.com - March 3 at 5:55 PM
Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer’s Disease CandidateAvid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer’s Disease Candidate
finance.yahoo.com - March 1 at 8:38 AM
Avid Bioservices (CDMO) Upgraded to Hold at Zacks Investment ResearchAvid Bioservices (CDMO) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - February 27 at 7:54 PM
Avid Bioservices (CDMO) Announces Resignation of CFOAvid Bioservices (CDMO) Announces Resignation of CFO
www.streetinsider.com - February 27 at 5:32 PM
Avid Bioservices (CDMO) Announces Resignation of CFO - StreetInsider.comAvid Bioservices (CDMO) Announces Resignation of CFO - StreetInsider.com
www.streetinsider.com - February 27 at 8:48 AM
Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant SciencesAvid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
finance.yahoo.com - February 21 at 8:48 AM
Insider Buying: Avid Bioservices Inc (CDMO) Director Purchases 50,000 Shares of StockInsider Buying: Avid Bioservices Inc (CDMO) Director Purchases 50,000 Shares of Stock
www.americanbankingnews.com - February 20 at 9:46 PM
Avid Bioservices Announces Closing of Public Offering of Common StockAvid Bioservices Announces Closing of Public Offering of Common Stock
finance.yahoo.com - February 20 at 5:25 PM
Want To Invest In Avid Bioservices Inc (NASDAQ:CDMO)? Here’s How It Performed LatelyWant To Invest In Avid Bioservices Inc (NASDAQ:CDMO)? Here’s How It Performed Lately
finance.yahoo.com - February 16 at 8:39 AM
Avid Bioservices (CDMO) Plans Offering of Common StockAvid Bioservices (CDMO) Plans Offering of Common Stock
www.streetinsider.com - February 15 at 8:12 AM
Avid Bioservices Announces Proposed Offering of Common StockAvid Bioservices Announces Proposed Offering of Common Stock
finance.yahoo.com - February 14 at 5:12 PM
Head to Head Review: Peregrine Pharmaceuticals (CDMO) and Its PeersHead to Head Review: Peregrine Pharmaceuticals (CDMO) and Its Peers
www.americanbankingnews.com - February 10 at 11:40 AM
Peregrine Pharmaceuticals (CDMO) versus Its Competitors Head-To-Head ContrastPeregrine Pharmaceuticals (CDMO) versus Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - February 10 at 3:12 AM
Peregrine Pharmaceuticals (CDMO) versus The Competition Head to Head SurveyPeregrine Pharmaceuticals (CDMO) versus The Competition Head to Head Survey
www.americanbankingnews.com - February 9 at 10:12 AM
Head-To-Head Survey: Peregrine Pharmaceuticals (CDMO) versus Its CompetitorsHead-To-Head Survey: Peregrine Pharmaceuticals (CDMO) versus Its Competitors
www.americanbankingnews.com - February 6 at 7:14 PM
Head to Head Contrast: Peregrine Pharmaceuticals (CDMO) & Its PeersHead to Head Contrast: Peregrine Pharmaceuticals (CDMO) & Its Peers
www.americanbankingnews.com - February 5 at 1:39 PM
Critical Analysis: Peregrine Pharmaceuticals (CDMO) versus Its CompetitorsCritical Analysis: Peregrine Pharmaceuticals (CDMO) versus Its Competitors
www.americanbankingnews.com - February 5 at 11:06 AM
Analyzing Peregrine Pharmaceuticals (CDMO) and The CompetitionAnalyzing Peregrine Pharmaceuticals (CDMO) and The Competition
www.americanbankingnews.com - February 5 at 5:12 AM
Peregrine Pharmaceuticals (CDMO) and Its Rivals Head-To-Head SurveyPeregrine Pharmaceuticals (CDMO) and Its Rivals Head-To-Head Survey
www.americanbankingnews.com - February 4 at 5:08 PM
Contrasting Peregrine Pharmaceuticals (CDMO) & Its CompetitorsContrasting Peregrine Pharmaceuticals (CDMO) & Its Competitors
www.americanbankingnews.com - February 4 at 1:20 PM
Analyzing Auxilium Pharmaceuticals (AUXL) and Peregrine Pharmaceuticals (CDMO)Analyzing Auxilium Pharmaceuticals (AUXL) and Peregrine Pharmaceuticals (CDMO)
www.americanbankingnews.com - February 3 at 11:18 PM
Avid Bioservices to Present at NobleCon14Avid Bioservices to Present at NobleCon14
finance.yahoo.com - January 31 at 10:01 AM
Comparing Peregrine Pharmaceuticals (CDMO) & Its RivalsComparing Peregrine Pharmaceuticals (CDMO) & Its Rivals
www.americanbankingnews.com - January 29 at 5:14 PM

SEC Filings

Avid Bioservices (NASDAQ:CDMO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Avid Bioservices (NASDAQ:CDMO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Avid Bioservices (NASDAQ CDMO) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.